The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use~~ A method of treating or preventing a disorder in which the blocking of purine receptors is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (1):



(I)

wherein

R_1 is optionally substituted C_1-C_6alkyl C_2-C_6alkenyl, or C_2-C_6alkynyl, or $-NR_6R_7$. $-OR_8$, -SR_9 or halogen;

R_2 is optionally substituted aryl or heteroaryl attached via a carbon atom;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl l, C_3-C_7 cycloalkyl, aryl or heteroaryl,

R_5 is H or optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7cycloalkyl; or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;

R_6 is H or optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7 cycloalkyl;

R_7, R_8, R_9 and R_{10} are optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3C_7 cycloalkyl or

R_6 and R_7 together form a 5 or 6-membered heterocyclic ring;

~~and~~ or a pharmaceutically acceptable ~~salts and prodrugs~~ salt or prodrug thereof~~, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial~~.

2. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_1 is halogen,

optionally substituted C_1-C_3alkyl, C_2-C_3alkenyl, or $-NR_6R_7$. $-OR_8$, $-SR_9$;wherein R_6 is H or optionally substituted C_1-C_3alkyl, and R_7, R_8, and R_9 are C_1-C_3alkyl, or R_6 and R_7 together form a 5 or 6-membered heterocyclic ring.

3. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_1 is methyl, ethyl, n- or iso-propyl, trifuoromethyl, allyl, cyclopropyl, chloro, bromo or fluoro.

4. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_1 is $-NR_6R_7$. $-OR_8$, $-SR_9$;wherein R_6 is hydrogen, methyl, ethyl, n- or iso-propyl, trifuoromethyl,or allyl; R_7 is methyl, ethyl, n- or iso-propyl; R_8 and R_9 are methyl, ethyl, n- or iso-propyl, trifluoromethyl or allyl.

5. (Currently Amended) The ~~use~~ method as claimed in claim 1 wherein R_1 is $-NHCH_3$.

6. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_2 is optionally substituted phenyl.

7. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R_2 is optionally substituted monocyclic or bicyclic heteroaryl.

8. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R_2 is optionally substituted furyl, thienyl, thiazolyl, oxazolyl imidazolyl, pyridyl, indolyl or benzofuranyl.

9. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein optional substituents present in R_2 are selected from C_1-C_3 alkyl, C_1-C_3 alkoxy, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups.

10. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 8~~ claim 1 wherein optional substituents present in R_2 are selected from methyl, ethyl, methoxy, ethoxy, cyclopropyl chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups $-CONR^AR^B$ where R^A and R^B are independently hydrogen, methyl or ethyl.

11. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R_2 is 2-furyl, 5-methyl-2 furyl, 2-thiazolyl, 4-methyl-2-thiazolyl. phenyl, or o-methyl-phenyl.

12. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_3 is H, C_1-C_6alkyl, C_3-C_6 cycloalkyl, halo substituted C_1-C_6alkyl, or halogen.

13. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 11~~ claim 1 wherein R_3 is H, methyl, ethyl, n- or isopropyl, cyclopropyl, n-, sec- or tert-butyl, trifloromethyl, chloro, bromo or fluoro.

14. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_4 is C_1-C_6alkyl, substituted by aryl or heteroaryl, the said aryl or heteroaryl ring being optionally substituted.

15. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 is arylmethyl or heteroarylmethyl, the said aryl or heteroaryl ring being optionally substituted.

16. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.

17. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, imidazolyl, pyrazolyl, and isoxazolyl.

18. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 14 to 17~~ claim 14 wherein optional substituents are selected from C_1-C_6alkyl, C_1-C_3 alkoxy, chloro, bromo,

fluoro, trifluoromethyl, $-NR^AR^B$, $-CONR^AR^B$, $-NR^ACOR^B$ where R^A and R^B are independently hydrogen or C_1-C_3 alkyl or together form an optionally substituted 5 or 6-membered heterocyclic ring.

19. (Currently Amended) The ~~use~~ method as claimed in ~~any of the preceding claims~~ claim 1 wherein R_5 is hydrogen.

20. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 and R_5 taken together with the nitrogen to which they are attached form a saturated 5 or 6-membered heterocyclic ring, optionally benz-fused.

21. (Currently Amended) The ~~use~~ method as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 and R_5 taken together with the nitrogen to which they are attached form a dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl ring system.

22. (Canceled)

23. (Currently Amended) A compound of formula (I): ~~as defined in any of claims 1 to 21,~~



(I)

wherein

R_1 is optionally substituted C_1-C_6alkyl C_2-C_6alkenyl, or C_2-C_6alkynyl, or $-NR_6R_7$, $-OR_8$, $-SR_9$ or halogen;

R_2 is optionally substituted 5-membered heteroaryl;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl l, C_3-C_7 cycloalkyl, aryl or heteroaryl,
R_5 is H or optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7cycloalkyl; or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;
R_6 is H or optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7 cycloalkyl;
R_7, R_8, R_9 and R_{10} are optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3C_7 cycloalkyl or
R_6 and R_7 together form a 5 or 6-membered heterocyclic ring;
or a pharmaceutically acceptable salt or prodrug thereof.

24. (Original) A compound as claimed in claim 23 wherein the compound is selected from any of the compounds as shown in Table 1.

25. (Currently Amended) ~~For use in therapy~~ A therapy comprising administering an effective amount of a compound as claimed in ~~claims 23 or 24~~ claim 23.

26. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 23 ~~or claim 24~~ in combination with a pharmaceutically acceptable carrier or excipients.

27. (Currently Amended) A ~~use as claimed in any of claims 1 to 21 or a~~ method as claimed in claim ~~22~~ 1 wherein said receptors are adenosine receptors.

28. (Currently Amended) A ~~use as claimed in any of claims 1 to 21 or a~~ method as claimed in claim ~~22~~ 1 wherein said receptors are adenosine A_{2A} receptors.

29. (Currently Amended) A ~~use as claimed in any of claims 1 to 21 or a~~ method as claimed in claim ~~22~~ 1 wherein the disorders are selected from movement disorders; anxiety disorders, affective disorders; central and peripheral nervous system degenerative disorders; schizophrenia; cognitive and memory impairment disorders; attention disorders; central nervous system injury; cerebral ischaemia; myocardial ischaemia; muscle ischaemia; sleep

disorders; eye disorders; cardiovascular disorders; and diabetes.

30. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the movement disorder is selected from Parkinson's disease, progressive supernuclear palsy, Huntingtons disease, muhiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism and spasticity.

31. (Currently Amended) A ~~use or~~ method as claimed in claim 29 ~~or claim 30~~, wherein the disorder is a movement disorder and the compound of formula (I) is used or administered together with L-DOPA or a dopamine agonist.

32. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the anxiety disorder is selected from panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.

33. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said affective disorder is selected
from bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease.

34. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said central and peripheral nervous system degenerative disorder is selected from corticobasal degeneration, demyelinating disease, Freidrich's ataxia, motoneurone disease, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy, systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.

35. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said cognitive and/or memory . impairment disorder is selected from dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory

impairment, cognitive impairment associated with dementia, Korsakoff syndrome, dementia pugilans;

36. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein attention disorder is selected from attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood and hyperactive child syndrome.

37. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said central nervous system injury is selected from traumatic brain injury, surgical trauma, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.

38. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said cerebral ischaemia is transient ischaemic attack, stroke, subarachnoid haemorrhage, cerebral vasospasm, perinatal asphyxia, drowning, cardiac arrest or subdural haematoma.

39. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the sleep disorder is selected from hypersomnia, narcolepsy and restless legs syndrome.

40. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the eye disorder is selected from retinal ischaemia-reperfusion injury and diabetic neuropathy.

41. (Canceled)

42. (Currently Amended) A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I): ~~as set out in any of claims 1 to 21~~



(I)

wherein

R_1 is optionally substituted C_1-C_6alkyl C_2-C_6alkenyl, or C_2-C_6alkynyl, or $-NR_6R_7$, $-OR_8$, $-SR_9$ or halogen;

R_2 is optionally substituted aryl or heteroaryl attached via a carbon atom;

R_3 is H; optionally substituted C_1-C_6alkyl, C_2-C_6alkenyl, C_2alkynyl, or C_3-C_7 cycloalkyl, halogen; OH or OR_{10};

R_4 is H, optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl l, C_3-C_7 cycloalkyl, aryl or heteroaryl,

R_5 is H or optionally substituted C_1-C_6alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7cycloalkyl; or R_4 and R_5 together form a 5 or 6-membered heterocyclic ring;

R_6 is H or optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3-C_7 cycloalkyl;

R_7, R_8, R_9 and R_{10} are optionally substituted C_1-C_3alkyl, C_3-C_6alkenyl, C_3-C_6alkynyl, or C_3C_7 cycloalkyl or

R_6 and R_7 together form a 5 or 6-membered heterocyclic ring;

or a pharmaceutically acceptable salt or prodrug thereof.